活血通络清脑饮联合奥扎格雷钠对老年短暂性脑缺血发作患者神经功能的影响(1)
摘要 目的：探討活血通络清脑饮联合奥扎格雷钠对老年短暂性脑缺血发作(TIA)患者神经功能的影响。方法：选取2016年8月至2017年12月南通大学附属海安医院收治的老年TIA患者124例作为研究对象，并随机分为观察组和对照组，每组62例。2组均接受常规对症治疗，对照组在常规治疗基础上给予奥扎格雷钠，观察组在对照组的基础上加用血通络清脑饮。2组均以10 d为1个治疗周期，连续治疗2个周期后进行临床疗效观察，并定期随访6个月。比较2组临床疗效，检测并比较2组患者治疗前后神经功能及血小板活性指标变化，随访期间比较2组患者预后。结果：治疗后观察组与对照组的总有效率分别为75.81%、56.45%，观察组总有效率高于对照组，差异有统计学意义(P<0.05)。治疗后2组眩晕症状及中风先兆症状评分均低于治疗前，且观察组低于对照组，差异有统计学意义(P<0.05)。治疗后2组神经元特异性烯醇化酶(NSE)、S100B蛋白(S-100B)、神经胶质纤维酸性蛋白(GFAP)、血小板聚集率、血小板α-颗粒膜糖蛋白(GMP-140)、血小板活性因子(PAF)水平低于治疗前，且观察组低于对照组，差异有统计学意义(P<0.05)。治疗后2组美国国立卫生研究院神经功能评分量表(NHISS)评分低于治疗前，日常生活能力量表(Barthel)评分高于治疗前，且2组差异有统计学意义(P<0.05)。观察组复发率、局灶性神经功能缺损发生率低于对照组，差异有统计学意义(P<0.05)，但2组心血管事件发生率，差异无统计学意义(P>0.05)。结论：血通络清脑饮联合奥扎格雷钠治疗老年TIA疗效显著，可改善血小板活性及神经功能，且患者临床复发率、局灶性神经功能缺损发生率较低。
关键词 短暂性脑缺血发作;活血通络清脑饮;奥扎格雷钠;神经功能;血小板活性
Abstract Objective：To explore the efficacy of Huoxue Tongluo Qingnao Powder combined with ozagrel sodium on neurological function in elderly patients with transient ischemic attack (TIA).Methods：A total of/Totally 124 cases of elderly TIA patients in Haian Hospital Affiliated to Nantong University from August 2016 to December 2017 were selected and randomly divided into the observation group and the control group，with 62 cases in each group.The 2 groups received routine symptomatic treatment，while the control group was given ozagrel sodium on the basis of conventional treatment.The observation group was additionally given Huoxue Tongluo Qingnao Powder on the basis of the control group.The 2 groups were treated with 10 d for 1 treatment cycle，and the clinical efficacy was observed after 2 cycles of treatment.The patients in the 2 groups were followed-up regularly for 6 months.The clinical efficacy of the 2 groups was compared，and the changes of nerve function and platelet activation function indexes of the 2 groups were detected and compared.The prognosis of patients in 2 groups was compared during the follow-up period.Results：The total effective rate of the observation group and the control group were 75.81% and 56.45% respectively after treatment，and the total effective rate of the observation group was significantly higher than that of the control group (P<0.05).The scores of vertigo symptoms and symptoms of apoplexy aura of the 2 groups after treatment were lower than before treatment (P<0.01)，and the observation group was lower than the control group (P<0.01).The levels of NSE，S-100B，GFAP，platelet aggregation，GMP-140 and PAF of the 2 groups after treatment were lower than those before treatment (P<0.05 or P<0.01)，and the observation group was lower than that of the control group (P<0.01).The NHISS scores of the 2 groups after treatment were lower than that before treatment，and the Barthel score was higher than that before treatment，and there was a significant difference between the 2 groups (P<0.01).The incidence of recurrent and focal neurological deficits in the observation group was significantly lower than that of the control group (P<0.05)，but there was no significant difference in the incidence of cardiovascular events between the 2 groups (P>0.05).Conclusion：Huoxue Tongluo Qingnao Powder combined with ozagrel sodium is effective in the treatment of elderly TIA patients.It can improve platelet activity and nerve function，and the clinical recurrence rate and the incidence of focal neurological deficit are lower.It is worthy of clinical popularization., http://www.100md.com(曹建 谢海洋 秦延昆)
关键词 短暂性脑缺血发作;活血通络清脑饮;奥扎格雷钠;神经功能;血小板活性
Abstract Objective：To explore the efficacy of Huoxue Tongluo Qingnao Powder combined with ozagrel sodium on neurological function in elderly patients with transient ischemic attack (TIA).Methods：A total of/Totally 124 cases of elderly TIA patients in Haian Hospital Affiliated to Nantong University from August 2016 to December 2017 were selected and randomly divided into the observation group and the control group，with 62 cases in each group.The 2 groups received routine symptomatic treatment，while the control group was given ozagrel sodium on the basis of conventional treatment.The observation group was additionally given Huoxue Tongluo Qingnao Powder on the basis of the control group.The 2 groups were treated with 10 d for 1 treatment cycle，and the clinical efficacy was observed after 2 cycles of treatment.The patients in the 2 groups were followed-up regularly for 6 months.The clinical efficacy of the 2 groups was compared，and the changes of nerve function and platelet activation function indexes of the 2 groups were detected and compared.The prognosis of patients in 2 groups was compared during the follow-up period.Results：The total effective rate of the observation group and the control group were 75.81% and 56.45% respectively after treatment，and the total effective rate of the observation group was significantly higher than that of the control group (P<0.05).The scores of vertigo symptoms and symptoms of apoplexy aura of the 2 groups after treatment were lower than before treatment (P<0.01)，and the observation group was lower than the control group (P<0.01).The levels of NSE，S-100B，GFAP，platelet aggregation，GMP-140 and PAF of the 2 groups after treatment were lower than those before treatment (P<0.05 or P<0.01)，and the observation group was lower than that of the control group (P<0.01).The NHISS scores of the 2 groups after treatment were lower than that before treatment，and the Barthel score was higher than that before treatment，and there was a significant difference between the 2 groups (P<0.01).The incidence of recurrent and focal neurological deficits in the observation group was significantly lower than that of the control group (P<0.05)，but there was no significant difference in the incidence of cardiovascular events between the 2 groups (P>0.05).Conclusion：Huoxue Tongluo Qingnao Powder combined with ozagrel sodium is effective in the treatment of elderly TIA patients.It can improve platelet activity and nerve function，and the clinical recurrence rate and the incidence of focal neurological deficit are lower.It is worthy of clinical popularization., http://www.100md.com(曹建 谢海洋 秦延昆)
参见：首页 > 医疗版 > 疾病专题 > 神经内科 > 脑血管病 > 短暂性脑缺血发作